Developing novel complement activation assays for application in basic and clinical research
Studying the cross-talk between complement and TLRs, in particular to the co-receptor CD14
Investigating the effect on inflammation by inhibiting complement activation and CD14 using human whole blood in vitro models and in vivo animal models of human diseases
Studying the “Thromboinflammation” and new complex whole blood models to reveal cross-talk between biological systems ex vivo
Studying complement activation in patients with diseases being tentative candidates for future complement intervention
Develop tools for evaluation of the effect of complement therapy in the clinic
Nygård Odeh K, Soløy Nilsen H, Gangsøy Kristiansen M, Brekke OL, Mollnes TE, Berk M(2025) Cytokines interferon-γ- inducible protein 10 and granulocyte-macrophage colony-stimulating factor are associated with psychiatric symptoms in opioid-dependent patients: A cross- sectional study PLoS One, 20(8), e0324365 DOI 10.1371/journal.pone.0324365, PubMed 40773504
Mollnes TE, Jager NM, Ottens PJ, Schjalm C, Veldhuis ZJ, Leuvenink HGD, Pischke SE(2025) Inhibition of the complement component C5 and the Toll-like receptor molecule CD14 prevents systemic and local kidney inflammation in mice experiencing brain death Sci Rep, 15(1), 27018 DOI 10.1038/s41598-025-12071-x, PubMed 40707525
Nygård-Odeh K, Soløy-Nilsen H, Gangsøy-Kristiansen M, Brekke OL, Mollnes TE, Berk M, Bramness JG(2025) Hostility is Associated with Interferon γ Inducible Protein 10 in Opioid Maintenance Treatment Patients with Chronic Hepatitis C Clin Psychopharmacol Neurosci, 23(3), 488-493 DOI 10.9758/cpn.24.1262, PubMed 40660694
